Warburg and Advent in the lead to acquire Baxter’s biopharma unit
A consortium of private equity firms, Warburg Pincus and Advent International, is in the final stages of negotiations to purchase Baxter International Inc.'s biopharma solutions business for an amount that could exceed $4 billion. This news was first reported by Reuters and has since been confirmed by Baxter. Other private equity firms and major biomedical companies, such as Thermo Fisher Scientific Inc., had also expressed interest in the auction.0
